Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley Interdiscip Rev Syst Biol Med 2011; 3: 216-230.W. Zwart, V. Theodorou, and J. S. Carroll, "Estrogen receptor- positive breast cancer: a multidisciplinary challenge," Wiley Interdisciplinary Reviews. Systems Biology and ...
Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Wiley Interdiscip. Rev. Syst. Biol. Med. 2011; 3 :216, 230.Zwart, W., Theodorou, V., and Carroll, J. S. (2011) Estrogen receptor-positive breast cancer: a multidisciplinary challenge. Systems Biol Med. 3, 216-230...
Estrogen and progesterone receptor (ER, PR) signaling control breast development and impinge on breast carcinogenesis. ER is an established driver of ER + disease but the role of the PR, itself an ER target gene, is debated. We assess the issue in clinically relevant settings by a geneti...
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
While CDK4/6 inhibitors (CDK4/6i) have improved outcomes for breast cancer patients, estrogen receptor (ER + ) breast cancers often develop resistance, and triple negative breast cancer (TNBC) show poor sensitivity. Here, the authors identify a vulnerability of CDK4/6i treated ER+ and ...
BMC Cancer. 2009; 9 (1):243.S Buechler.Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer. BMC Cancer . 2009Buechler, (2009), " Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer, " BMC Cancer,...
Approximately 70% of invasive breast cancers express estrogen receptor (ER), and the majority of ER positive cancers also express progesterone receptor (PgR). Although the presence of normal PgR levels suggests an intact ER signal transduction pathway in breast cancer cells, discrepant ER and PgR ...
Targeting of mutant-p53 and MYC as a novel strategy to inhibit oncogenic SPAG5 activity in triple negative breast cancer Valeria Canu , Sebastiano Vaccarella & Giovanni Blandino Article 13 August 2024 | Open Access UBE2M forms a positive feedback loop with estrogen receptor to drive brea...
Meaning The combination of clinical and molecular information may enhance the prognostic value for distant recurrence and risk stratification in estrogen receptor–positive, ERBB2-negative breast cancer, particularly for women with node-positive disease. Abstract Importance Multiple molecular signatures are av...
ER expression levels affect the prognosis of breast cancer. The risk for patients with weakly ER-positive breast cancer should not be underestimated. 展开 关键词: Breast neoplasm Estrogen receptor Prognosis DOI: 10.1007/s10549-018-4948-y 年份: 2018 ...